ストックスクリーナーアプリを入手
12.79
4.41%
0.54
前日終値:
$12.25
開ける：
$12.15
24時間の取引高:
3.14M
Relative Volume:
1.95
時価総額：
$808.35M
収益：
$15.84M
当期純損益:
$-308.48M
株価収益率:
-1.9738
EPS:
-6.48
ネットキャッシュフロー:
$-153.08M
1週間 パフォーマンス:
-13.41%
1か月 パフォーマンス:
+39.63%
6か月 パフォーマンス:
+64.18%
1年 パフォーマンス:
+152.27%
1日の値動き範囲:
$11.82
$13.77
1週間の範囲:
$10.05
$16.20
52週間の値動き範囲:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
QURE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
12.79 | 808.35M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-01 | 再開されました | Chardan Capital Markets | Buy |
| 2024-12-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-02-29 | ダウングレード | Goldman | Buy → Neutral |
| 2023-12-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-17 | アップグレード | UBS | Neutral → Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-05-21 | 開始されました | UBS | Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-01 | アップグレード | Mizuho | Neutral → Buy |
| 2021-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-09 | 開始されました | Jefferies | Buy |
| 2020-11-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-08-25 | 開始されました | Raymond James | Strong Buy |
| 2020-07-31 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-06-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | 開始されました | Cowen | Outperform |
| 2019-12-03 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Outperform |
| 2019-10-11 | 開始されました | Stifel | Buy |
| 2019-09-25 | 開始されました | Bernstein | Outperform |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-07-30 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-07-08 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Uniqure N V (QURE) 最新ニュース
Is uniQure (NASDAQ:QURE) A Risky Investment? - simplywall.st
Uniqure NV earnings beat by $0.18, revenue fell short of estimates - Investing.com India
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - Yahoo Finance
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating R - GuruFocus
Transcript : UniQure N.V., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
QURE's Financial Position Strengthened by Recent Capital Raise | - GuruFocus
UniQure: Q1 Earnings Snapshot - MySA
uniQure (QURE) Reports Lower Q1 Revenue, Advances Huntington's T - GuruFocus
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Est - GuruFocus
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode By Stocktwits - Investing.com India
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Estimates, Revenue Falls Short at $1.6 Million - GuruFocus
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress - GlobeNewswire
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
uniQure (QURE) Stock Decline Viewed as Overreaction by Analysts | QURE Stock News - GuruFocus
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha
(QURE) Proactive Strategies - news.stocktradersdaily.com
Uniqure NV expected to post a loss of $1.01 a shareEarnings Preview - TradingView
uniQure (QURE) Receives Steady "Buy" Rating from Chardan Capital - GuruFocus
uniQure to Announce First Quarter 2025 Financial Results - GlobeNewswire
Gene Therapy Leader uniQure Launches Quarterly Earnings Calls as AMT-130 Nears BLA Submission - Stock Titan
UniQure stock holds $70 target, buoyed by FDA breakthrough nod - Investing.com Australia
(QURE) Investment Analysis - news.stocktradersdaily.com
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance
uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha
uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN
AMT-130 gets FDA breakthrough therapy designation - European Biotechnology Magazine
FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com Canada
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga
uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus
uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus
uniQure shares soar on FDA breakthrough therapy designation - Investing.com
uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com Canada
FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com
uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | - GuruFocus
UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus
Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView
uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq
uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease - Yahoo
uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World
Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com
Uniqure N V (QURE) 財務データ
収益
当期純利益
現金流量
EPS
Uniqure N V (QURE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '25 |
Sale |
10.29 |
10,438 |
107,407 |
217,730 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '25 |
Sale |
10.29 |
7,076 |
72,812 |
119,743 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 25 '25 |
Sale |
10.70 |
26,727 |
285,979 |
571,188 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 27 '25 |
Sale |
11.32 |
6,717 |
76,036 |
580,795 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 25 '25 |
Sale |
10.70 |
14,341 |
153,449 |
152,372 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 27 '25 |
Sale |
11.32 |
2,916 |
33,009 |
155,168 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Option Exercise |
14.71 |
100,000 |
1,471,000 |
697,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):